A recent study demonstrated that PD–L1 expression and EMT markers in CTCs negatively correlate with NSCLC patient survival [42], suggesting the diagnostic potential of the anti-PD–L1 aptamer in this tumor type. The gene discussed is CD274; the disease is non-small cell lung carcinoma.